# SURVIVE (intensive versus standard surveillance in early breast cancer)

Source: https://onco.cc/trials/survive-breast-surveillance/  
OnCo record `survive-breast-surveillance` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A large German study asking whether regular blood tests after breast cancer treatment, rather than waiting for symptoms, change what happens to women.

## Summary

SURVIVE (NCT05658172) compares standard with intensive surveillance in 3,500 planned patients with early breast cancer; in the intensive arm, abnormal blood results trigger imaging. It is the parent study of SURVIVE HERoes, which randomises patients with HER2-positive or HER2-low disease who have a molecular relapse.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Also known as: SURVIVE
- Registry id: NCT05658172
- Phase: not-applicable
- Setting: Intermediate- and high-risk early breast cancer after primary treatment: standard surveillance compared with intensive surveillance that adds blood tests (tumour markers, circulating tumour cells and ctDNA)
- Sponsor: Prof. Wolfgang Janni
- Enrolled: 3500

## Sources

- ClinicalTrials.gov NCT05658172: https://clinicaltrials.gov/study/NCT05658172

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)
- trials: [SURVIVE HERoes](https://onco.cc/trials/survive-heroes/)

---
JSON: https://onco.cc/api/v1/entities/survive-breast-surveillance.json